# Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus

> **NCT01547104** · PHASE4 · UNKNOWN · sponsor: **Marcus Borchert** · enrollment: 40 (estimated)

## Conditions studied

- Diabetes Mellitus Type 2

## Interventions

- **DRUG:** Linagliptin
- **DRUG:** Glimepiride

## Key facts

- **NCT ID:** NCT01547104
- **Lead sponsor:** Marcus Borchert
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-04
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2012-04-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01547104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01547104, "Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01547104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*